Skip to content

A two-part, open-label study to assess the pharmacokinetics, pharmacodynamics and safety of single doses of inhaled and intravenously administered D,L lysine acetylsalicylate • glycine (LASAG) in healthy adult subjects: Study Part A follows a randomized, cross-over design to compare three dose levels of inhaled LASAG to one dose level of intravenously administered LASAG and Study Part B follows a single group design to investigate a XXXXX LASAG inhalation solution.

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2022-503037-63-00
Acronym
ASPI-AAP-006-01
Enrollment
28
Registered
2023-05-19
Start date
2023-08-17
Completion date
2024-02-21
Last updated
2024-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical trial in healthy males and females intended indication: migraine, Phase I

Interventions

None listed

Sponsors

Aspiair GmbH
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026